Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.
Company profile
Ticker
JNJ
Exchange
Website
CEO
Alex Gorsky
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
JOHNSON & JOHNSON ET AL
SEC CIK
Corporate docs
Subsidiaries
ABD Holding Company, Inc. • ABIOMED COMMERCIAL, LLC • ABIOMED R&D, Inc. • ABIOMED, Inc. • Acclarent, Inc. • Actelion Pharmaceuticals US, Inc. • Albany Street LLC • ALZA Corporation • Alza Land Management, Inc. • AMO Development, LLC ...
IRS number
221024240
JNJ stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
13 Mar 24
DEFA14A
Additional proxy soliciting materials
13 Mar 24
DEFA14A
Additional proxy soliciting materials
13 Mar 24
10-K
2023 FY
Annual report
16 Feb 24
DFAN14A
Additional proxy materials by non-management
15 Feb 24
DFAN14A
Additional proxy materials by non-management
29 Jan 24
8-K
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
23 Jan 24
DFAN14A
Additional proxy materials by non-management
9 Jan 24
DFAN14A
Additional proxy materials by non-management
8 Jan 24
DEFA14A
Additional proxy soliciting materials
8 Jan 24
Transcripts
JNJ
Earnings call transcript
2023 Q4
23 Jan 24
JNJ
Earnings call transcript
2023 Q3
17 Oct 23
JNJ
Earnings call transcript
2023 Q2
20 Jul 23
JNJ
Earnings call transcript
2023 Q1
18 Apr 23
JNJ
Earnings call transcript
2022 Q4
24 Jan 23
JNJ
Earnings call transcript
2022 Q3
18 Oct 22
JNJ
Earnings call transcript
2022 Q2
19 Jul 22
JNJ
Earnings call transcript
2022 Q1
19 Apr 22
JNJ
Earnings call transcript
2021 Q4
25 Jan 22
JNJ
Earnings call transcript
2021 Q3
19 Oct 21
Latest ownership filings
4
Vanessa Broadhurst
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
Eugene A. Woods
7 Mar 24
4
MARILLYN A HEWSON
7 Mar 24
4
CVRx, Inc.
6 Mar 24
4
Jennifer L Taubert
20 Feb 24
4
Kathryn E Wengel
20 Feb 24
4
Timothy Schmid
20 Feb 24
4
William Hait
20 Feb 24
4
James D. Swanson
20 Feb 24
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jan 23 | Jan 22 | Jan 21 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.73 bn | 19.73 bn | 19.73 bn | 19.73 bn | 19.73 bn | 19.73 bn |
Cash burn (monthly) | 485.00 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 2.72 bn | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 17.00 bn | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 35.1 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
51.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3250 |
Opened positions | 276 |
Closed positions | 603 |
Increased positions | 1094 |
Reduced positions | 1608 |
13F shares | Current |
---|---|
Total value | 173.84 tn |
Total shares | 1.23 bn |
Total puts | 5.13 mm |
Total calls | 4.06 mm |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 229.39 mm | $35.95 tn |
STT State Street | 132.90 mm | $20.83 tn |
MS Morgan Stanley | 41.66 mm | $6.53 tn |
Whalerock Point Partners | 35.41 mm | $5.55 bn |
JPM JPMorgan Chase & Co. | 29.75 mm | $4.66 tn |
NTRS Northern Trust | 29.73 mm | $4.66 tn |
Capital International Investors | 28.99 mm | $4.54 tn |
Wellington Management | 24.02 mm | $3.76 tn |
BK Bank Of New York Mellon | 22.23 mm | $3.48 tn |
LGEN Legal & General | 22.10 mm | $3.46 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 24 | Vanessa Broadhurst | Common Stock | Sell | Dispose S | No | No | 162.16 | 8,891 | 1.44 mm | 15,043 |
5 Mar 24 | Marillyn A Hewson | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 159.8 | 234.668 | 37.50 k | 8,787.744 |
5 Mar 24 | Woods Eugene A. | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 159.8 | 261.993 | 41.87 k | 753.446 |
5 Mar 24 | Woods Eugene A. | Deferred Share Units Common Stock | Grant | Acquire A | No | No | 159.8 | 491.453 | 78.53 k | 491.453 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 5.141 | 79 | 406.14 | 4,103,430 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 3.955 | 252 | 996.66 | 4,103,351 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 1.186 | 142 | 168.41 | 4,103,099 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 1.186 | 442 | 524.21 | 4,102,957 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 0.237 | 300 | 71.10 | 4,102,515 |
29 Feb 24 | Johnson & Johnson | Common Stock | Option exercise | Acquire M | Yes | No | 0.237 | 584 | 138.41 | 4,102,215 |
News
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
18 Mar 24
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
14 Mar 24
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
14 Mar 24
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
13 Mar 24
Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
13 Mar 24
Press releases
Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge
12 Mar 24
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
11 Mar 24
Johnson & Johnson Completes Acquisition of Ambrx
7 Mar 24
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
1 Mar 24
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
20 Feb 24